MedTrace Logo

Eszopiclone and Inflammatory Mediators in Patients With Acute Coronary Syndrome

NCT00822679 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-12-20

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to examine the effects of Eszopiclone, a sleep aid, on inflammatory mediators and coagulability in patients with a recent myocardial infarction.

Conditions

  • Acute Coronary Syndrome
  • Sleep Disorder

Interventions

DRUG

Eszopiclone

Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.

OTHER

Placebo

Subjects are given placebo for 3 consecutive nights

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    collaborator INDUSTRY

  • Southern Arizona VA Health Care System

    collaborator FED

  • University of Arizona

    lead OTHER

Principal Investigators

  • Sairam Parthasarathy, MD · Southern Arizona VA Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-08-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00822679 on ClinicalTrials.gov